Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.

IF 1.9 Q3 PHARMACOLOGY & PHARMACY
Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-10-30 DOI:10.5582/ddt.2023.01078
Manabu Suzuki, Akihiro Matsunaga, Tohru Miyoshi-Akiyama, Junko Terada-Hirashima, Kenji Sadamasu, Mami Nagashima, Jin Takasaki, Shinyu Izumi, Masayuki Hojo, Yukihito Ishizaka, Haruhito Sugiyama
{"title":"Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.","authors":"Manabu Suzuki, Akihiro Matsunaga, Tohru Miyoshi-Akiyama, Junko Terada-Hirashima, Kenji Sadamasu, Mami Nagashima, Jin Takasaki, Shinyu Izumi, Masayuki Hojo, Yukihito Ishizaka, Haruhito Sugiyama","doi":"10.5582/ddt.2023.01078","DOIUrl":null,"url":null,"abstract":"<p><p>During an earlier multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of high-dose inhaled ciclesonide in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19), we observed that worsening of shadows on CT without worsening of clinical symptoms was more common with ciclesonide. The present study sought to determine if an association exists between worsening CT shadows and impaired antibody production in patients treated with inhaled ciclesonide. Eighty-nine of the 90 patients in the original study were prospectively enrolled. After exclusions, there were 36 patients each in the ciclesonide and control groups. We analyzed antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein at various time points. Changes in viral load during treatment were compared. There was no significant difference in age, sex, body mass index, background clinical characteristics, or symptoms between the two groups. Although evaluation on day 8 suggested a greater tendency for worsening shadows on CT in the ciclesonide group (p = 0.072), there was no significant difference between them in the ability to produce antibodies (p = 0.379) or the maximum antibody titer during the clinical course. In both groups, worsening CT shadows and higher viral loads were observed on days 1-8, suggesting ciclesonide does not affect clearance of the virus (p = 0.134). High-dose inhaled ciclesonide did not impair production of antibodies against SARS-CoV-2 or affect elimination of the virus, suggesting that this treatment can be used safely in patients with COVID-19 patients who use inhaled steroids for asthma and other diseases.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"304-311"},"PeriodicalIF":1.9000,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discoveries and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/ddt.2023.01078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

During an earlier multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of high-dose inhaled ciclesonide in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19), we observed that worsening of shadows on CT without worsening of clinical symptoms was more common with ciclesonide. The present study sought to determine if an association exists between worsening CT shadows and impaired antibody production in patients treated with inhaled ciclesonide. Eighty-nine of the 90 patients in the original study were prospectively enrolled. After exclusions, there were 36 patients each in the ciclesonide and control groups. We analyzed antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein at various time points. Changes in viral load during treatment were compared. There was no significant difference in age, sex, body mass index, background clinical characteristics, or symptoms between the two groups. Although evaluation on day 8 suggested a greater tendency for worsening shadows on CT in the ciclesonide group (p = 0.072), there was no significant difference between them in the ability to produce antibodies (p = 0.379) or the maximum antibody titer during the clinical course. In both groups, worsening CT shadows and higher viral loads were observed on days 1-8, suggesting ciclesonide does not affect clearance of the virus (p = 0.134). High-dose inhaled ciclesonide did not impair production of antibodies against SARS-CoV-2 or affect elimination of the virus, suggesting that this treatment can be used safely in patients with COVID-19 patients who use inhaled steroids for asthma and other diseases.

吸入ciclesonide不会影响新冠肺炎患者抗体的产生或病毒的消除:一项多中心、开放标签随机试验的亚分析。
在早期的一项多中心、开放标签、随机对照试验中,我们观察到ciclesonide在CT阴影恶化而临床症状恶化的情况下更常见,该试验旨在评估大剂量吸入ciclesonid对2019年无症状或轻度冠状病毒病(新冠肺炎)患者的有效性。本研究试图确定吸入环索奈德治疗患者的CT阴影恶化与抗体产生受损之间是否存在关联。在最初的研究中,90名患者中有89名是前瞻性入选的。排除后,ciclesonide组和对照组各有36名患者。我们分析了不同时间点针对严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)核衣壳蛋白的抗体滴度。比较治疗期间病毒载量的变化。两组在年龄、性别、体重指数、背景临床特征或症状方面没有显著差异。尽管第8天的评估表明,ciclesonide组的CT阴影有更大的恶化趋势(p=0.072),但在产生抗体的能力(p=0.379)或临床过程中的最大抗体滴度方面,他们之间没有显著差异。在这两组中,在第1-8天观察到CT阴影恶化和病毒载量增加,这表明ciclesonide不影响病毒的清除(p=0.134)。高剂量吸入ciclesonid不会损害抗严重急性呼吸系统综合征冠状病毒2型抗体的产生或影响病毒的消除,表明这种治疗可以安全地用于新冠肺炎患者,这些患者使用吸入类固醇治疗哮喘和其他疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Discoveries and Therapeutics
Drug Discoveries and Therapeutics PHARMACOLOGY & PHARMACY-
CiteScore
3.20
自引率
3.20%
发文量
51
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信